Stem cell differentiation refers to the method that involves the hematopoiesis mechanism which gives rise to new bone marrow cells. Some of the methods which are patented are given below.
Patent no: 7,132,287 titled ‘Method for neural stem cell differentiation using 5HT-1A agonists’ with the abstract: The present invention relates to a method for differentiating a neural stem cell into a neuronal cell such as a neuroblast or a neuron in vitro or in vivo. Particularly, the invention provides for a method for neural stem cell differentiation by contacting the neural stem cell with a 5HT1A ligand or agonist.
Patent no: 6,841,386 titled ‘Modulation of primary stem cell differentiation using an insulin-like growth factor binding protein’ with the abstract: The present invention features methods of modulating primary stem cell differentiation in culture by altering the endogenous activity of an insulin-like growth factor.
Patent no: 6,534,052 titled ‘Cardiac function comprising implantation of embryonic stem cell in which differentiation has been initiated’ with the abstract: The present invention is a method for markedly improving cardiac function and repairing heart tissue in a living mammalian subject after the occurrence of a myocardial infarction. The method is a surgical technique which introduces and implants mammalian embryonic stem cells into the infarcted area of the myocardium. After implantation, the embryonic stem cells form stable grafts and survive indefinitely within the infarcted area of the heart in the living host. The demonstrated beneficial effects of the method include a decreased infarcted area and improved cardiac function as assessed by hemodynamic and echocardiographic measurements.
Patent no: 6,255,112 titled ‘Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells’ with the abstract : The invention relates to the induction of hematopoietic stem cells to differentiate into osteoclasts by culturing hematopoietic stem cells with human mesenchymal stem cells, and, in a preferred embodiment, using no exogenous cytokines. Differentiation of the mesenchymal stem cells into osteoblasts inhibited the differentiation of hematopoietic stem cells into osteoclasts. In addition, hematopoietic stem cells can be genetically engineered to carry genes of interest particularly for the expression of physiologically active proteins. In the presence of mesenchymal stem cells, the transduced cells carry the new genetic material and express gene products that can be used to modulate bone resorption.
Patent no: 5,942,225 titled ‘Lineage-directed induction of human mesenchymal stem cell differentiation’ with the abstract : Methods for in vitro or ex vivo lineage directed induction of isolated, culture expanded human mesenchymal stem cells comprising contacting the mesenchymal stem cells with a bioactive factor effective to induce differentiation thereof into a lineage of choice as well as such compositions including isolated culture expanded human mesenchymal stem cells and bioactive factors effective to induce directed lineage induction are disclosed. Further disclosed is this method which also includes introducing such culturally expanded lineage-induced mesenchymal stem cells into a host from which they have originated for purposes of mesenchymal tissue regeneration or repair.
Patent no: 7,132,286 titled ‘Method for neural stem cell differentiation using valproate’ with the abstract: The present invention relates to a method for differentiating a neural stem cell into a neuronal cell such as a neuroblast or neuron in vitro or in vivo. Particularly, the invention provides for a method for neural stem cell differentiation by contacting the neural stem cell with a valproate compound or analog thereof.
Join Free Patent Lessons Course
